27
EHDV-TAU, a Novel Oncolytic Virus
Ramot At Tel Aviv University
Oncolytic Virotherapy
Oncology
Target Identification or Validation
Unmet Needs
On Nov. 2015 the FDA approved the first oncolytic virus based treatment. Oncolytic viruses are a promising category of anti-cancer therapeutic agents that have a dual action: 1) kill cancer cells directly and specifically and 2) stimulate of anti-tumor immunity. Viral characteristics such as size, genome composition, lytic abilities etc. determine the interactions of oncolytic viruses with cancer cells. There is a need for an oncolytic virus with markedly different characteristics to target tumors which do not respond to current viral- and/or immune-therapies.
Virus Development
Directed evolution enabled to develop the oncolytic virus, EHDV-TAU. A clone of the epizootic hemorrhagic disease virus selected on interferon-defective human prostate cells. The directed evolution process increased the viral replication by 10E7 (10 million fold) on this subset of human prostate cancer cells. Virus was tested on multiple tumor models. Infection of tumors is inversely correlated to IFN/JAK/STAT signaling.
Ehrlich Marcelo,
Eran Bacharach
US 11484558 B2 (2022.11.01)
• "Lipocalin-2 regulates the expression of interferon-stimulated genes and the susceptibility of prostate cancer cells to oncolytic virus infection". Barer, L., et al. Eur J Cell Biol, 2023. 102(2): p. 151328.
• "Oncolytic virotherapy: the cancer cell side". Ehrlich, M. et al. Cancers 2021, 13(5), 939
• "Constitutive low expression of antiviral effectors sensitizes melanoma cells to a novel oncolytic virus". Dellac, S. et al. International Journal of Cancer 2020, 148(9), 2321–2334
• "Interleukin-6 and Interferon-alpha Signaling via JAK1-STAT Differentially Regulate Oncolytic versus Cytoprotective Antiviral States". Danziger, O., et al. Front Immunol, 2018. 9: p. 94.
• "Combined genetic and epigenetic interferences with interferon signaling expose prostate cancer cells to viral infection". Danziger, O., et al. Oncotarget, 2016. 7(32): p. 52115-52134.
